So You've Bought Irritable Bowel Syndrome With Constipation Drugs ... Now What?
Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episode of diarrhea with accompanying abdominal pain. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit. Rifaximin (Xifaxan) is an antibiotic approved in May 2015 by the U.S. Food and Drug Administration (FDA) for treatment of IBS with diarrhea (IBS-D) in adults. Also, it works by reducing or altering bacteria in the gut. However, it has been found to improve IBS symptoms of bloating and diarrhea after a 10?14-day course of treatment.
Get PDF Brochure: https://bit.ly/3kucT2W

The report also includes the profiles of key players in irritable bowel syndrome with constipation drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Actavis
- Astellas Pharmaceuticals
- AstraZenenca
- GlaxoSmithKline
- Pfizer
- Salix Pharmaceuticals Ltd
- Actavis
- Astellas Pharmaceuticals
- AstraZenenca
- GlaxoSmithKline
- Pfizer
- Salix Pharmaceuticals Ltd
Comments
Post a Comment